

Instance: composition-en-553de2aa690a5750d1825c26ecd3f9ed
InstanceOf: CompositionUvEpi
Title: "Composition for gefitinib Package Leaflet"
Description:  "Composition for gefitinib Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - gefitinib"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  What is in this leaflet 
 
1. What Gefitinib Mylan is and what it is used for  
2. What you need to know before you take Gefitinib Mylan 
3. How to take Gefitinib Mylan 
4. Possible side effects  
5. How to store Gefitinib Mylan 
6. Contents of the pack and other information 
         </div>"""   
          

* section[=].section[+]
  * title =  "1. What gefitinib is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What gefitinib is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Gefitinib Mylan contains the active substance gefitinib which blocks a protein called  epidermal 
growth factor receptor  (EGFR). This protein is involved in the growth and spread of cancer cells. </p>
<p>Gefitinib Mylan is used to treat adults with non-small cell lung cancer. This cancer is a disease in 
which malignant (cancer) cells form in the tissues of the lung. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Gefitinib Mylan:</p>
<ul>
<li>if you are allergic to gefitinib or any of the other ingredients of this medicine (listed in 
section 6). </li>
<li>if you are breast-feeding. </li>
</ul>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Gefitinib Mylan 
- if you have ever had any other lung problems. Some lung problems may get worse during 
treatment with Gefitinib Mylan. 
- if you have ever had problems with your liver. 
- if you have ever had stomach problems (gastrointestinal perforation) </p>
<p>Tell your doctor immediately if you experience dehydration or eye problems whilst taking this 
medicine (see section 4). </p>
<p>Children and adolescents 
Gefitinib Mylan is not indicated in children and adolescents under 18 years. </p>
<p>Other medicines and Gefitinib Mylan 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines as they 
may affect the way gefitinib works:</p>
<ul>
<li>Phenytoin or carbamazepine (for epilepsy). </li>
<li>Rifampicin (for tuberculosis). </li>
<li>Itraconazole (for fungal infections). </li>
<li>Barbiturates (a type of medicine used for sleeping problems). </li>
<li>Herbal remedies containing St John s wort (Hypericum perforatum, used for depression and 
anxiety). </li>
<li>Proton-pump inhibitors, H2-antagonists and antacids (for ulcers, indigestion, heartburn and to 
reduce acids in the stomach). </li>
<li>Warfarin (a so-called oral anticoagulant, to prevent blood clots). If you are taking a medicine 
containing this active substance, your doctor may need to do blood tests more often. 
If any of the above applies to you, or if you are not sure, check with your doctor or pharmacist before 
taking Gefitinib Mylan. </li>
</ul>
<p>Pregnancy and breast-feeding 
Talk to your doctor if you are pregnant, may become pregnant or are breast-feeding. </p>
<p>It is recommended that you avoid becoming pregnant during treatment with this medicine because 
Gefitinib Mylan could harm your baby. </p>
<p>Do not take Gefitinib Mylan if you are breast-feeding. This is for the safety of your baby. </p>
<p>Driving and using machines 
You may feel weak while taking treatment with this medicine. If this happens, do not drive or use any 
tools or machines. </p>
<p>Gefitinib Mylan contains lactose<br />
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>
<p>Gefitinib Mylan contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially<br />
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<ul>
<li>The recommended dose is one 250 mg tablet per day. </li>
<li>Take the tablet at about the same time each day. </li>
<li>The tablet should be swallowed with some water, with or without food. </li>
<li>Do not take antacids (to reduce the acid level of your stomach) 2 hours before or 1 hour after 
taking Gefitinib Mylan. </li>
</ul>
<p>If you have trouble swallowing the tablet, dissolve it in half a glass of still (non-fizzy) water. Do not 
use any other liquids. Do not crush the tablet. Swirl the water until the tablet has dissolved. This may 
take up to 20 minutes. Drink the liquid straight away.<br />
To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of 
water and drink it. </p>
<p>If you take more Gefitinib Mylan than you should 
If you have taken more tablets than you should, talk to a doctor or pharmacist straight away. </p>
<p>If you forget to take Gefitinib Mylan </p>
<p>What to do if you forget to take a tablet depends on how long it is until your next dose. 
* If it is 12 hours or more until your next dose: take the missed tablet as soon as you remember. 
Then take the next dose as usual. 
* If it is less than 12 hours until your next dose: skip the missed tablet. Then take the next tablet at 
the usual time. 
Do not take a double dose (two tablets at the same time) to make up for a forgotten dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Tell your doctor immediately if you notice any of the following side effects - you may need urgent 
medical treatment: 
* Allergic reaction (common), particularly if symptoms include swollen face, lips, tongue or 
throat, difficulty to swallow, hives, nettle rash and difficulty breathing. 
* Serious breathlessness, or sudden worsening breathlessness, possibly with a cough or fever. This 
may mean that you have an inflammation of the lungs called  interstitial lung disease . This may 
affect about 1 in 100 patients taking gefitinib and can be life-threatening. 
* Severe skin reactions (rare) affecting large areas of your body. The signs may include redness, 
pain, ulcers, blisters, and shedding of the skin. The lips, nose, eyes and genitals may also be 
affected. 
* Dehydration (common) caused by long term or severe diarrhoea, vomiting (being sick), nausea 
(feeling sick) or loss of appetite. 
* Eye problems (uncommon), such as pain, redness, watery eyes, light sensitivity, changes in 
vision or ingrowing eyelashes. This may mean that you have an ulcer on the surface of the eye 
(cornea). </p>
<p>Tell your doctor as soon as possible if you notice any of the following side effects: </p>
<p>Very common (may affect more than 1 in 10 people) 
* Diarrhoea. 
* Vomiting. 
* Nausea. 
* Skin reactions such as an acne-like rash, which is sometimes itchy with dry and/or cracked skin. 
* Loss of appetite. 
* Weakness. 
* Red or sore mouth. 
* Increase of a liver enzyme known as alanine aminotransferase in a blood test; if too high, your 
doctor may tell you to stop taking this medicine. </p>
<p>Common (may affect up to 1 in 10 people) 
* Dry mouth. 
* Dry, red or itchy eyes. 
* Red and sore eyelids. 
* Nail problems. 
* Hair loss. 
* Fever. 
* Bleeding (such as nose bleed or blood in your urine). 
* Protein in your urine (shown in a urine test). 
* Increase of bilirubin and the other liver enzyme known as aspartate aminotransferase in a blood 
test; if too high, your doctor may tell you to stop taking this medicine. 
* Increase of creatinine levels in a blood test (related to kidney function). </p>
<ul>
<li>Cystitis (burning sensations during urination and frequent, urgent need to urinate). </li>
</ul>
<p>Uncommon (may affect up to 1 in 100 people) 
* Inflammation of the pancreas. The signs include very severe pain in the upper part of the 
stomach area and severe nausea and vomiting. 
* Inflammation of the liver. Symptoms may include a general feeling of being unwell, with or 
without possible jaundice (yellowing of the skin and eyes). This side effect is uncommon; 
however, some patients have died from this. 
* Gastrointestinal perforation. 
* Skin reaction on the palms of the hands and soles of the feet including tingling, numbness, pain, 
swelling or reddening (known as palmar-plantar erythrodysaesthesia syndrome or hand and foot 
syndrome). </p>
<p>Rare (may affect up to 1 in 1 000 people) 
* Inflammation of the blood vessels in the skin. This may give the appearance of bruising or 
patches of non-blanching rash on the skin. 
* Haemorrhagic cystitis (burning sensations during urination and frequent, urgent need to urinate 
with blood in the urine). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects, you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store gefitinib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store gefitinib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and carton or pouch after 
EXP. The expiry date refers to the last day of that month. </p>
<p>Do not store above 30 C. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Gefitinib Mylan contains<br />
- The active substance is gefitinib. Each film-coated tablet contains 250 mg of gefitinib.<br />
- The other ingredients are lactose monohydrate, microcrystalline cellulose (101), crospovidone 
(type A), povidone (K30), sodium laurilsulfate, magnesium stearate in the tablet core. The tablet 
coating contains polyvinyl alcohol (E1203), macrogol 4000 (E1521), talc (E553b), titanium dioxide 
(E171), red iron oxide (E172), yellow iron oxide (E172). </p>
<p>What Gefitinib Mylan looks like and contents of the pack 
Gefitinib Mylan tablets are brown, round, biconvex film-coated tablets with approximately 11.1 mm x 
5.6 mm of dimension and marked with  250  on one side and plain on the other. 
It comes in PVC/PVDC/Aluminium blisters in packs of 30 film-coated tablets or in 
PVC/PVDC/Aluminium perforated unit dose blisters in packs of 30x1 film-coated tablets. The blisters 
may be packed into aluminium pouches. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Mylan Pharmaceuticals Limited 
Damastown Industrial Park 
Mulhuddart, Dublin DUBLIN 
Ireland </p>
<p>Manufacturer 
Ardena Pamplona S.L. 
Pol gono Mochol <br />
C/ No in, N  1<br />
31110 No in (Navarra)<br />
Spain </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61<br />
Lietuva 
Mylan Healthcare UAB<br />
Tel: +370 5 205 1 </p>
<p>: +359 2 44 55<br />
Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ. s.r.o. 
Tel: + 420 222 004 Magyarorsz g 
Mylan EPD Kft. 
Tel.: + 36 1 465 2 </p>
<p>Danmark 
Viatris ApS 
Tlf: + 45 28 11 69 32  </p>
<p>Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH<br />
Tel: + 49 800 0700<br />
Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti 
filiaal<br />
Tel: + 372 6363<br />
Norge 
Viatris AS 
Tlf: + 47 66 75 33  </p>
<p>Generics Pharma Hellas  <br />
 :  +30 210 993 6410  </p>
<p>sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 </p>
<p>Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102<br />
Polska 
Mylan Healthcare Sp. z.o.o. 
Tel.: + 48 22 546 64<br />
France 
Viatris Sant<br />
T l: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska 
Mylan Hrvatska d.o.o. <br />
Tel: +385 1 23 50<br />
Rom nia 
BGP Products SRL 
Tel: +40 372 579<br />
Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711 
Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
 sland 
Icepharma hf. 
Simi: + 354 540 8 
Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199<br />
Italia 
Mylan Italia S.r.l 
Tel: + 39 02 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 </p>
<p>Varnavas Hadjipanayis Ltd 
 : + 357 2220 7 
Sverige 
Viatris AB<br />
Tel: + 46 (0)8 630 19<br />
Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711 
This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

